Mark Hanley

CEO, VirTrial

Mark Hanley is a visionary in the healthcare industry who has dedicated his career to improving the quality of care across multiple disciplines. As CEO of VirTrial, a ground-breaking telehealth platform provider, Hanley is currently focused on driving responsible and measured innovation in the clinical trial industry. Hanley sold VirTrial in 2020 to Signant Health, the leading enabler of evidence generation for modern clinical trials.

In support of the clinical site trial industry and Hanley’s commitment to site sustainability, in 2019 he acquired and became CEO of Society of Clinical Research Sites (SCRS) where he is currently Chairman and CEO.

With a long history contributing to the clinical trial industry, Hanley most recently served as the Chief Executive Officer of Radiant Research, which he built into the country’s largest wholly-owned network of clinical trial sites. In 2016, Radiant acquired Synexus to become the largest site network in the world, consisting of over 200 sites in 11 countries.

Hanley’s early career positions all supported his goal of improving healthcare. He served as the Chief Executive Officer and President of O2 Science, Inc. a large regional provider of home healthcare products and services and Executive Director of Transworld Healthcare (UK) Limited from 1995 to 1997. He has been a consultant to numerous companies in the healthcare industry, an Independent Director of Allied Healthcare International Inc., and currently serves on several boards including the Society for Clinical Research Sites (SCRS), Synzi-Telehealth services, Stratus Video, as well as ZVRS, an industry leader in communication access services, and is currently Chairman of the Board at StudyKIK.

Hanley is an active community volunteer and a prior Court Appointed Special Advocate (CASA), a role that he held since 2007. The mission of a CASA is to advocate for the best interests of abused and neglected children who are involved in the juvenile court system.